Skip to main content

Advertisement

Table 3 Antimicrobial activity of antimicrobial agents against Acinetobacter baumannii , Haemophilus influenzae and Pseudomonas aeruginosa collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

  MIC 90 (mg/L) MIC range mg/L % susceptible % resistant
Acinetobacter baumannii (n = 16,778)   
AMK ≥128 ≤0.5 – ≥ 128 61.1 32.4
AMC ≥64 ≤0.12 – ≥ 64 - -
AMP ≥64 ≤0.5 – ≥ 64 - -
FEP ≥64 ≤0.5 – ≥ 64 44.3 42.9
CAZ ≥64 ≤8 – ≥ 64 41.2 52.1
CRO ≥128 ≤0.06 – ≥ 128 23.3 54.6
IPM (n = 3,795) ≥32 ≤0.06 – ≥ 32 80.0 16.8
LVX ≥16 ≤0.008 – ≥ 16 43.0 46.6
MEM (n = 12,983) ≥32 ≤0.06 – ≥ 32 54.8 41.1
MIN 8 ≤0.5 – ≥ 32 84.5 5.1
TZP ≥256 ≤0.06 – ≥ 256 42.9 47.5
TGC 2 ≤0.008 – ≥ 32 - -
Acinetobacter baumannii, MDR (n = 6,743)   
AMK ≥128 ≤0.5 – ≥ 128 18.4 74.1
AMC ≥64 1 – ≥ 64 - -
AMP ≥64 ≤0.5 – ≥ 64 - -
FEP ≥64 ≤0.5 – ≥ 64 5.5 80.1
CAZ ≥64 ≤8 – ≥ 64 4.0 90.8
CRO ≥128 ≤0.06 – ≥ 128 0.7 94.6
IPM (n = 896) ≥32 0.25 – ≥ 32 30.9 64.6
LVX ≥16 0.03 – ≥ 16 2.4 89.3
MEM (n = 5,847) ≥32 ≤0.06 – ≥ 32 11.9 84.0
MIN 16 ≤0.5 – ≥ 32 70.3 11.3
TZP ≥256 ≤0.06 – ≥ 256 3.0 90.5
TGC 2 ≤0.008 – ≥ 32 - -
Haemophilus influenzae (n = 15,925)    
AMK 8 ≤0.5 – ≥ 128 - -
AMC 1 ≤0.12 – ≥ 64 99.7 0.3
AMP 32 ≤0.5 – ≥ 64 78.3 19.3
FEP ≤0.5 ≤0.5 – ≥ 64 99.5 -
CRO ≤0.06 ≤0.06 – 32 99.9 -
IPM (n = 3,672) 1 ≤0.06 – ≥ 32 99.9 -
LVX 0.03 ≤0.008 – ≥ 16 99.9 -
MEM (n = 12,253) 0.12 ≤0.06 – 2 99.9 -
MIN 1 ≤0.5 – ≥ 32 98.6 0.5
TZP ≤0.06 ≤0.06 – 64 99.8 0.2
TGC 0.25 ≤0.008 – 4 98.9 -
Haemophilus influenzae, BL-pos (n = 3,207)    
AMK 8 ≤0.5 – ≥ 128 - -
AMC 2 ≤0.12 – ≥ 64 98.9 1.1
AMP ≥64 ≤0.5 – ≥ 64 0.2 95.2
FEP ≤0.5 ≤0.5 – ≥ 64 99.1 -
CRO ≤0.06 ≤0.06 – 16 99.9 -
IPM (n = 803) 1 ≤0.06 – 4 100 -
LVX 0.03 ≤0.008 – ≥ 16 99.8 -
MEM (n = 2,404) 0.12 ≤0.06 – 2 99.8 -
MIN 1 ≤0.5 – ≥ 32 98.4 0.5
TZP ≤0.06 ≤0.06 – 64 99.7 0.3
TGC 0.25 ≤0.008 – 1 99.0 -
Pseudomonas aeruginosa (n = 28,413)    
AMK 16 ≤0.5 – ≥ 128 90.2 6.5
AMC ≥64 ≤0.12 – ≥ 64 - -
AMP ≥64 ≤0.5 – ≥ 64 - -
FEP 32 ≤0.5 – ≥ 64 74.3 13.5
CAZ 32 ≤8 – ≥ 64 74.0 18.1
CRO ≥128 ≤0.06 – ≥ 128 - -
IPM (n = 6,303) 8 ≤0.06 – ≥ 32 76.4 17.5
LVX ≥16 ≤0.008 – ≥ 16 63.9 29.5
MEM (n = 22,110) 16 ≤0.06 – ≥ 32 70.3 22.3
MIN ≥32 ≤0.5 – ≥ 32 - -
TZP 128 ≤0.06 – ≥ 256 73.1 15.3
TGC 16 ≤0.008 – ≥ 32 - -
Pseudomonas aeruginosa, MDR (n = 3,496)    
AMK ≥128 ≤0.5 – ≥ 128 46.3 43.5
AMC ≥64 1 – ≥ 64 - -
AMP ≥64 ≤0.5 – ≥ 64 - -
FEP ≥64 ≤0.5 – ≥ 64 8.2 69.0
CAZ ≥64 ≤8 – ≥ 64 11.7 77.7
CRO ≥128 2 – ≥ 128 - -
IPM (n = 557) ≥32 0.5 – ≥ 32 5.9 92.1
LVX ≥16 0.03 – ≥ 16 2.1 96.3
MEM (n = 2,939) ≥32 ≤0.06 – ≥ 32 4.9 91.8
MIN ≥32 ≤0.5 – ≥ 32 - -
TZP ≥256 0.25 – ≥ 256 10.9 67.7
TGC ≥32 ≤0.008 – ≥ 32 - -
  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.